Intraurethral and topical agents

Ronald W Lewis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In early 1997, the FDA approved a transurethral delivery system for a urethral suppository containing alprostadil (PGE1), manufactured by Vivus and called the MUSE® system. Pharmacokinetic studies showed rapid absorption from the urethra (80%) in the first 10 minutes after an intraurethral dose. 873 patients tried home use of alprostadil or blinded placebos. 64.9% of the patients on alprostadil reported intercourse compared to only 18.6% of the placebo group. Successful use of MUSE® at home seemed to be equal in all categories of impotence. The consistency of response increased slightly over a period of 3 months. Penile pain occurred in 32.1% of patients receiving the active ingredient (10.8% of all applications). With the MUSE® system, there was minor urethral trauma in 5.1% of the patients. A small subset of patients who used MUSE® reported that previous intracavernosal injection therapy was not effective. Of these, 58% reported erections sufficient for intercourse after MUSE® introduction. Recently, further efficacy studies were performed in a FDA trial of the combination of the MUSE® system with the veno- occlusive band (Actis®). Topical medications have been anecdotally reported and do not produce spectacular results. These include organic nitrates and nitrites, minoxidil, papaverine and PGE1 or PGE2. (C) 2000 Prous Science.

Original languageEnglish (US)
Pages (from-to)113-119
Number of pages7
JournalDrugs of Today
Volume36
Issue number2-3
DOIs
StatePublished - Jan 1 2000

Fingerprint

Alprostadil
Placebos
Minoxidil
Suppositories
Papaverine
Erectile Dysfunction
Urethra
Nitrites
Dinoprostone
Nitrates
Pharmacokinetics
Pain
Injections
Wounds and Injuries

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Intraurethral and topical agents. / Lewis, Ronald W.

In: Drugs of Today, Vol. 36, No. 2-3, 01.01.2000, p. 113-119.

Research output: Contribution to journalArticle

Lewis, Ronald W. / Intraurethral and topical agents. In: Drugs of Today. 2000 ; Vol. 36, No. 2-3. pp. 113-119.
@article{fb3b79816dc94459ac7b026baa6a9ec7,
title = "Intraurethral and topical agents",
abstract = "In early 1997, the FDA approved a transurethral delivery system for a urethral suppository containing alprostadil (PGE1), manufactured by Vivus and called the MUSE{\circledR} system. Pharmacokinetic studies showed rapid absorption from the urethra (80{\%}) in the first 10 minutes after an intraurethral dose. 873 patients tried home use of alprostadil or blinded placebos. 64.9{\%} of the patients on alprostadil reported intercourse compared to only 18.6{\%} of the placebo group. Successful use of MUSE{\circledR} at home seemed to be equal in all categories of impotence. The consistency of response increased slightly over a period of 3 months. Penile pain occurred in 32.1{\%} of patients receiving the active ingredient (10.8{\%} of all applications). With the MUSE{\circledR} system, there was minor urethral trauma in 5.1{\%} of the patients. A small subset of patients who used MUSE{\circledR} reported that previous intracavernosal injection therapy was not effective. Of these, 58{\%} reported erections sufficient for intercourse after MUSE{\circledR} introduction. Recently, further efficacy studies were performed in a FDA trial of the combination of the MUSE{\circledR} system with the veno- occlusive band (Actis{\circledR}). Topical medications have been anecdotally reported and do not produce spectacular results. These include organic nitrates and nitrites, minoxidil, papaverine and PGE1 or PGE2. (C) 2000 Prous Science.",
author = "Lewis, {Ronald W}",
year = "2000",
month = "1",
day = "1",
doi = "10.1358/dot.2000.36.2-3.568784",
language = "English (US)",
volume = "36",
pages = "113--119",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "2-3",

}

TY - JOUR

T1 - Intraurethral and topical agents

AU - Lewis, Ronald W

PY - 2000/1/1

Y1 - 2000/1/1

N2 - In early 1997, the FDA approved a transurethral delivery system for a urethral suppository containing alprostadil (PGE1), manufactured by Vivus and called the MUSE® system. Pharmacokinetic studies showed rapid absorption from the urethra (80%) in the first 10 minutes after an intraurethral dose. 873 patients tried home use of alprostadil or blinded placebos. 64.9% of the patients on alprostadil reported intercourse compared to only 18.6% of the placebo group. Successful use of MUSE® at home seemed to be equal in all categories of impotence. The consistency of response increased slightly over a period of 3 months. Penile pain occurred in 32.1% of patients receiving the active ingredient (10.8% of all applications). With the MUSE® system, there was minor urethral trauma in 5.1% of the patients. A small subset of patients who used MUSE® reported that previous intracavernosal injection therapy was not effective. Of these, 58% reported erections sufficient for intercourse after MUSE® introduction. Recently, further efficacy studies were performed in a FDA trial of the combination of the MUSE® system with the veno- occlusive band (Actis®). Topical medications have been anecdotally reported and do not produce spectacular results. These include organic nitrates and nitrites, minoxidil, papaverine and PGE1 or PGE2. (C) 2000 Prous Science.

AB - In early 1997, the FDA approved a transurethral delivery system for a urethral suppository containing alprostadil (PGE1), manufactured by Vivus and called the MUSE® system. Pharmacokinetic studies showed rapid absorption from the urethra (80%) in the first 10 minutes after an intraurethral dose. 873 patients tried home use of alprostadil or blinded placebos. 64.9% of the patients on alprostadil reported intercourse compared to only 18.6% of the placebo group. Successful use of MUSE® at home seemed to be equal in all categories of impotence. The consistency of response increased slightly over a period of 3 months. Penile pain occurred in 32.1% of patients receiving the active ingredient (10.8% of all applications). With the MUSE® system, there was minor urethral trauma in 5.1% of the patients. A small subset of patients who used MUSE® reported that previous intracavernosal injection therapy was not effective. Of these, 58% reported erections sufficient for intercourse after MUSE® introduction. Recently, further efficacy studies were performed in a FDA trial of the combination of the MUSE® system with the veno- occlusive band (Actis®). Topical medications have been anecdotally reported and do not produce spectacular results. These include organic nitrates and nitrites, minoxidil, papaverine and PGE1 or PGE2. (C) 2000 Prous Science.

UR - http://www.scopus.com/inward/record.url?scp=0034102686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034102686&partnerID=8YFLogxK

U2 - 10.1358/dot.2000.36.2-3.568784

DO - 10.1358/dot.2000.36.2-3.568784

M3 - Article

C2 - 12879108

AN - SCOPUS:0034102686

VL - 36

SP - 113

EP - 119

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 2-3

ER -